The availability of several effective and safe vaccines enables health systems to counteract annual influenza epidemics. However, the criteria of appropriateness and sustainability require that each citizen should receive the right vaccine. The value of each vaccine can be assessed within well-known frameworks, such as the Health Technology Assessment (HTA), a step that is fundamental to the process of allocating resources to vaccination strategies. The paper describes how HTA has been incorporated as an evidence-based tool to support the definition of Italian vaccination strategies, reports the results of the HTA report on the most recently available influenza vaccine in Italy (cell-based quadrivalent vaccine (QIVc)—Flucelvax® Tetra) and elaborates on current and future recommendations in the field of influenza vaccination. Recommendations issued by the Italian Ministry of Health foster the appropriate use of influenza vaccines from 2018–2019 onwards. Evidence of the value of newly available vaccines will hopefully support future decisions and promote the appropriate use of these vaccines on the basis of the characteristics of the target population. However, the success of influenza vaccination will also depend on citizens’ empowerment and engagement in the decision-making process.

Calabro, G. E., Specchia, M. L., Boccalini, S., Panatto, D., Rizzo, C., Merler, S., Ferriero, A. M., Di Pietro, M. L., Bonanni, P., De Waure, C., Strengthening the evidence-based approach to guiding effective influenza vaccination policies, <<VACCINES>>, 2020; 8 (3): 1-6. [doi:10.3390/vaccines8030342] [http://hdl.handle.net/10807/166115]

Strengthening the evidence-based approach to guiding effective influenza vaccination policies

Calabro;G. E.; Specchia;S.; Ferriero;A. M.; Di Pietro;P.; de Waure
2020

Abstract

The availability of several effective and safe vaccines enables health systems to counteract annual influenza epidemics. However, the criteria of appropriateness and sustainability require that each citizen should receive the right vaccine. The value of each vaccine can be assessed within well-known frameworks, such as the Health Technology Assessment (HTA), a step that is fundamental to the process of allocating resources to vaccination strategies. The paper describes how HTA has been incorporated as an evidence-based tool to support the definition of Italian vaccination strategies, reports the results of the HTA report on the most recently available influenza vaccine in Italy (cell-based quadrivalent vaccine (QIVc)—Flucelvax® Tetra) and elaborates on current and future recommendations in the field of influenza vaccination. Recommendations issued by the Italian Ministry of Health foster the appropriate use of influenza vaccines from 2018–2019 onwards. Evidence of the value of newly available vaccines will hopefully support future decisions and promote the appropriate use of these vaccines on the basis of the characteristics of the target population. However, the success of influenza vaccination will also depend on citizens’ empowerment and engagement in the decision-making process.
Inglese
Calabro, G. E., Specchia, M. L., Boccalini, S., Panatto, D., Rizzo, C., Merler, S., Ferriero, A. M., Di Pietro, M. L., Bonanni, P., De Waure, C., Strengthening the evidence-based approach to guiding effective influenza vaccination policies, <<VACCINES>>, 2020; 8 (3): 1-6. [doi:10.3390/vaccines8030342] [http://hdl.handle.net/10807/166115]
File in questo prodotto:
File Dimensione Formato  
vaccines-08-00342.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 218.2 kB
Formato Adobe PDF
218.2 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/166115
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact